Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. 1994

E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.

S-Ethylisothiourea was a potent competitive inhibitor of human nitric oxide synthase (NOS), with Ki values of 17, 36, and 29 nM for the inducible (i), endothelial (e), and neuronal (n) isozymes, respectively. Unlike some potent inhibitors of NOS, no time dependence was observed. S-Ethylisothiourea was not a detectable substrate for eNOS. S-Ethylisothiourea was also a potent inhibitor of mouse iNOS (Ki value of 5.2 nM), and its binding perturbed the spectrum of iNOS consistent with its altering the environment of the bound heme. The optimum binding of S-ethyl- and S-isopropylisothiourea relative to 70 other analogs suggested that these alkyl substitutions fit into a small hydrophobic pocket. Most isothioureas were 2-6-fold selective for the human iNOS (Ki for iNOS versus Ki for eNOS), with one being 19-fold selective. The cyclized mimics of S-ethylisothiourea, 2-NH2-thiazoline, and 2-NH2-thiazole, were also competitive inhibitors of human NOS. A third structural class of inhibitors, bisisothioureas, were, in general, the most selective in their inhibition of human iNOS. S,S'-(1,3-Phenylenebis(1,2-ethanediyl))bisisothiourea was 190-fold selective (Ki value of 0.047 microM against iNOS versus 9.0 microM against eNOS). These results demonstrate that potent and selective inhibition of human NOS isozymes is achievable.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007550 Isothiuronium An undecenyl THIOUREA which may have topical anti-inflammatory activity. AHR-1911,Isothiouronium,AHR 1911,AHR1911
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004790 Enzyme Induction An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis. Induction, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000594 Amino Acid Oxidoreductases A class of enzymes that catalyze oxidation-reduction reactions of amino acids. Acid Oxidoreductases, Amino,Oxidoreductases, Amino Acid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
January 1995, British journal of pharmacology,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
October 1996, Pharmacology, biochemistry, and behavior,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
July 1998, Naunyn-Schmiedeberg's archives of pharmacology,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
September 1999, Bioorganic & medicinal chemistry,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
January 1996, Biochimie,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
October 1996, European journal of pharmacology,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
August 2001, The Biochemical journal,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
November 1995, European journal of pharmacology,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
November 1997, Journal of medicinal chemistry,
E P Garvey, and J A Oplinger, and G J Tanoury, and P A Sherman, and M Fowler, and S Marshall, and M F Harmon, and J E Paith, and E S Furfine
October 2014, Acta crystallographica. Section D, Biological crystallography,
Copied contents to your clipboard!